1. Home
  2. CNOB vs TBPH Comparison

CNOB vs TBPH Comparison

Compare CNOB & TBPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo ConnectOne Bancorp Inc.

CNOB

ConnectOne Bancorp Inc.

HOLD

Current Price

$27.42

Market Cap

1.2B

Sector

Finance

ML Signal

HOLD

Logo Theravance Biopharma Inc.

TBPH

Theravance Biopharma Inc.

HOLD

Current Price

$17.85

Market Cap

993.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CNOB
TBPH
Founded
1982
2013
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.2B
993.7M
IPO Year
1996
N/A

Fundamental Metrics

Financial Performance
Metric
CNOB
TBPH
Price
$27.42
$17.85
Analyst Decision
Buy
Strong Buy
Analyst Count
2
5
Target Price
$29.50
$27.80
AVG Volume (30 Days)
286.1K
535.4K
Earning Date
01-29-2026
11-10-2025
Dividend Yield
2.60%
N/A
EPS Growth
N/A
N/A
EPS
1.30
0.58
Revenue
$295,956,000.00
$80,327,000.00
Revenue This Year
$47.80
$70.78
Revenue Next Year
$29.35
N/A
P/E Ratio
$21.27
$31.31
Revenue Growth
19.03
27.12
52 Week Low
$20.61
$7.90
52 Week High
$27.91
$20.33

Technical Indicators

Market Signals
Indicator
CNOB
TBPH
Relative Strength Index (RSI) 69.24 51.95
Support Level $27.15 $17.25
Resistance Level $27.91 $20.32
Average True Range (ATR) 0.78 0.72
MACD 0.22 -0.27
Stochastic Oscillator 81.93 21.01

Price Performance

Historical Comparison
CNOB
TBPH

About CNOB ConnectOne Bancorp Inc.

ConnectOne Bancorp Inc is a community-based, full-service New Jersey-chartered commercial bank. Substantially all loans are secured with various types of collateral, including business assets, consumer assets and commercial/residential real estate. Each borrower's ability to repay its loans is dependent on the conversion of assets, cash flows generated from the borrowers' business, real estate rental and consumer wages.

About TBPH Theravance Biopharma Inc.

Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).

Share on Social Networks: